Tamoxifen is an antiestrogen used in the adjuvant endocrine therapy of early breast cancer and malignant breast disorders. It is also used in women with anovulatory infertility caused by its stimulating effect on the secretion of the pituitary gonadotrophic hormones. In males it could increase the endogenous production of androgens. Because of these properties tamoxifen may be misused in some sports to treat the androgens suppression caused by the extensive abuse of anabolic androgenic steroids. A method for identification and confirmation of tamoxifen metabolites is described. Hydroxymetoxytamoxifen is detected in urine by gas chromatography and mass spectrometry in a selective ion monitoring method followed by the routine postrun in the screening of anabolic steroids. Once the hydroxymetoxytamoxifen is detected, confirmation of reported metabolites could be performed with a 5973 mass selective detector in the scan mode after solid-phase extraction by cationic exchange. This study also reports an excretion profile for a single dose of tamoxifen equivalent to 40 mg administrated orally to two males volunteers.
Introduction
Tamoxifen is an antiestrogen that is used in the adjuvant endocrine therapy of early breast cancer and malignant bre a s t d i s o rders. It is also used in women with anovulatory infert i l i t y caused by its stimulating effect on the secretion of the pituitary g o n a d o t rophic hormones. In males it could increase the endogenous production of androgens. Because of these pro p e rt i e s , tamoxifen may be misused in some sports to treat the andro g e n s s u p p ression caused by the extensive abuse of anabolic androgenic steroids. For this reason it was first included in the forbidden list by the International Olympic Committee (IOC) and later by the World Antidoping Agency (WADA) as an antioestrogenic agent prohibited only in males. Tamoxifen is extensively metabolized and excreted mainly in feces. Biphasic excretion has been re p o rted, and the terminal half-time may be longer than 7 days (1). J. We carried out an excretion profile for a single dosis of 40 mg of tamoxifen administered orally to two male volunteers in ord e r to select those metabolites that are suitable using the norm a l s c reening pro c e d u re for anabolics. Urine samples were collected f rom 0 to 168 h post-administration.
H y d roxymethoxytamoxifen was detected in urine by gas chromatography (GC)-mass selective detection (MSD) using a selective ion monitoring (SIM) method and a postrun macro, as is routine for the screening of anabolic steroids. Once the hydro x y methoxytamoxifen was detected, confirmation of re p o rt e d metabolites could be perf o rmed with a Hewlett Packard 6980/5973 (GC-MSD) in the scan mode, with previous extraction by solid phase with a copolymeric bonded phase containing h y d rophobic and sulfonic functional groups (ZSDAU020).
Experimental

Drug administration
A 40-mg dose of tamoxifen (Taxus) was administered orally to two healthy male volunteers. Both were 28-years old and didn't receive any kind of medication before or during the excre t i o n s t u d y. The study was conducted according to the rules of our Faculty Ethical Committee (Universidad de Chile, Santiago, Chile). Urine samples were collected prior to and 2, 4, 8, 12, 24, 48, 60, 72, 96, 120, 144, and 168 h after administration.
Materials
Tamoxifen (Taxus) was obtained from Te c n o f a rma (Santiago, Chile), tert-butyl methyl ether was from Merck (Darm s t a d t , G e rm a n y ) , β-g l u c u ronidase from E. Coli (the strenght of solution at 37°C was at least 140 U/mL) was from Roche (Mannheim, Germany), N-m e t h y l -N-t r i m e t h y l -s i l y l -t r i f l u o roacetamide (MSTFA ) was from Aldrich (St. Louis, MO), and chlort r i m e t h y l s i l a n (TMSCI) was from Merck. Dithioerythritol (2,3-dihyd roxybutano-1,4-dithiol) was from Sigma (Ontario, Canada). C h romatographic-grade water, dichloromethane, and isop ropanol were from EMD Chemicals (Gibbstown, NJ). Na 2 H P O 4 -2 H 2 O, NaH 2 P O 4 -H 2 O, K 2 C O 3 , and NH 4 
Instrumental
The analyses were perf o rmed in a Hewlett Packard 6890/5973 GC-MSD system. The GC was carried out using a 100% polydimethylsiloxane fused silica capillary column from Agilent Technologies (Palo Alto, CA) (HP1, 25-m × 0.2-mm i.d, 0.11-µm), operated in SIM and scan modes. The methods and GC-MSD parameters were diff e rent for the screening and confirmation pro c e d u res and are given below.
Methods
Screening
Two milliliters of urine were hydrolyzed with 50 µL of β-g l uc u ronidase from E. coli at pH 6 with 750 µL of phosphate buff e r (1.04 g of Na 2 H P O 4 -2 H 2 O and 6.07 g of NaH 2 P O 4 -H 2 O re s u l t i n g in a concentration of 100mM) during 1 h at 50°C. Extraction was c a rried out with 5 mL of tert-butyl methyl ether at pH 9.5 with 80 µL of 25% potassium carbonate solution. The extract was dried under nitrogen at 40°C. The dried extract was derivatized with 100 µL MSTFA -N H 4 I -d i t h i o e rythritol (1000:4:3) at 75°C for 30 min. Three microliters was injected into the GC-MSD in the split mode (1:10).
The GC-MSD parameters included a column flow of 0.2 mL/min of Helium. The injector temperature was 280ºC in the split mode. The oven temperature was programmed from 190°C to 235°C at a rate of 2°C/min and then from 235°C to 300°C at a rate of 15°C/min. The final time was 7 min. It was operated in the SIM mode using a postrun macro for anabolic steroids including ions m / z 58, 72, and 489 at the retention time of metabolite 2 of tamoxifen. (Figure 2 ).
Confirmation
Five milliliters of urine was hydrolyzed with 50 µL of β-g l u c u ronidase from E. coli at pH 6 with 750 µL of phosphate b u ffer (100mM) during 1 h at 50°C. Tamoxifen was used as the internal standard at 100 ng/mL. The samples were applied over the solid-phase column and eluted with dichloro m e t h a n ei s o p ropanol-ammonia (78:20:2) (5). The extract was dried under nitrogen at 40°C. Dried extracts w e re derivatized with 100 µL of MSTFA -T M S C l (1%, v/v) to reduce chro m a t o g r a p h i c b a c k g ro u n d p roduced by the derivatization mixture used in the screening step. Two microliters was injected into the GC-MSD in the splitless mode. The GC-MSD parameters included a constant column flow of 1 mL/min. The injector temperat u re was 250°C. The oven temperature was programmed from 130°C to 310°C at a rate of 17°C min, with a final time of 5 min. Operation was in the scan mode (scan range, 50-550 amu).
Results and Discussion
Analysis of urine samples showed that unchanged tamoxifen was not excreted. The Samples without enzymatic hydrolysis indicated a lower extraction re c o v e ry for metabolite M2, but metabolite M1 resulted in similar recoveries for hydrolyzed and nonhydro l y z e d samples. This could suggest a nonconjugated excretion of metabolite M1.
The fragmentation pattern of both metabolites was similar to the parent drug. The fragmentation generates, after α-c l e a v a g e , the ion at m / z 58 as the base peak, followed in abundance by the ion at m / z 72 ( Figure 3) .
A metabolic profile for M1 and M2 was obtained using tamoxifen as the internal standard because previous analysis of specimens showed that the parent drug was not detected. The re s u l t s of both excretion studies are presented in Figure 4 , showing a peak of excretion at 12 h for both metabolites. Using this method, the main metabolite, hydroxymethoxytamoxifen (M2), could be detected up to 7 days after administration.
H y d roxymethoxytamoxifen was detected in urine by the ro utine GC-MSD screening pro c e d u re for anabolic steroids by a SIM method followed by a postrun macro (Figure 2) . Once the h y d roxymethoxytamoxifen was detected, confirmation of both re p o rted metabolites could be perf o rmed by GC-MSD in the scan mode, changing liquid extraction by SPE because of the amphoteric nature of M1 metabolite.
